Nuvectis Pharma, Inc. (NASDAQ: NVCT)

Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on developing innovative precision medicines for the treatment of serious oncologic conditions with unmet medical need.

The company's lead product candidate is NXP900 a targeted therapy that inhibits the SRC and YES1 kinases.

NXP900 is designed to bind SRC and lock the kinase in its inactive conformation thereby blocking both its enzymatic activity and its scaffolding function.

Preclinical studies have shown antitumor activity in models of breast esophageal head and neck cancers and medulloblastoma.

As a clinical stage company Nuvectis Pharma, Inc. does not currently generate revenue from product sales.

Its revenue consists of upfront license payments milestone payments and potential future royalties from licensing agreements with the University of Edinburgh and the CRT Pioneer Fund.

The agreements require the company to pay success based milestones and tiered royalties on net sales should any product achieve commercial approval.

To date the company has received upfront payments and has made certain milestone payments under these arrangements.

In the SRC YES1 kinase inhibitor space Nuvectis Pharma, Inc. faces competition from established multi kinase inhibitors such as Dasatinib (SPRYCEL®) and bosutinib (BOSULIF®) which are approved for hematologic malignancies but have shown limited activity in solid tumors.

Other investigational agents like saracatinib have been studied in solid tumors but development was discontinued after early trials.

Nuvectis Pharma, Inc. differentiates NXP900 by inducing and locking SRC in its inactive conformation thereby inhibiting both catalytic and scaffolding functions which may provide a wider therapeutic window and greater selectivity.

The company holds a global exclusive license to NXP900 with patent protection covering the composition of matter that extends to April 2036 supporting its competitive position.

Nuvectis Pharma, Inc. serves patients with advanced solid tumors through its clinical trial programs.

Its customers include hospitals oncology clinics and clinical research organizations that administer the investigational drug NXP900 to trial participants.

If NXP900 receives regulatory approval the company anticipates selling to healthcare providers pharmacies and oncology treatment centers.